Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Interleukin 10 Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Interleukin 10 Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Interleukin 10 (IL-10) is an anti-inflammatory cytokine that plays a vital role in maintaining the balance of immune responses, allowing the clearance of infection while minimizing damage to the host. It is synthesized by various types of cells in the body, like NK cells, B-cells, and T-cells. It is a pro-inflammatory cytokine that plays a significant role in inhibiting cytokine production and Th1 and Th2 cell activation. Any infection or inflammatory condition that signals an infection in the body against which the level of IL-10 scaled causes an increase in IL-10 levels. Therefore, IL-10 is associated with many diseases like vascular diseases, Rheumatoid Arthritis, Acute Myelogenous Leukemia, Blood Platelet disorders, various kinds of lymphomas like Follicular lymphoma, and others. It has also been linked with many neurodegenerative diseases wherein it played a role in preventing inflammation-mediated neuronal degradation. Hence, it acts to avoid inflammation in disorders such as Multiple Sclerosis, Alzheimer’s disease, Parkinson’s disease, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (AML), and others. Research is being conducted globally to discover new and novel molecules to be used as H1 Histamine antagonists. The development and launch of new products will thus increase the revenue of the market in the forecasted years. According to the Parkinson’s Foundation, more than 10 million people are living with Parkinson’s disease globally, while 90,000 people are diagnosed with it each year in the USA alone. It is projected that 1.2 million people in the USA will live with Parkinson’s by 2030. Therefore, there is ample opportunity for the market players globally.
A number of these inhibitors are in the market, while many are in ongoing clinical trials. Various companies have various products in their pipelines, with 49 products in different stages of clinical trials, with 2 in Phase 3, 16 in Phase 2, and 7 in Phase 1 of the clinical trials.
Drugs in the Pipeline of IL-10
Clinical Activity and Developments of Interleukin 10 (IL-10)
As of June 2023, various companies have approximately 49 products for 581 diseases. For these diseases, many trials are being conducted by players globally. For instance,
|
Molecule name |
Number of studies |
|
Eyevinal (ibudilast) |
27 |
|
orismilast oral (LEO 32731) |
12 |
|
pegilodecakin (LY3500518) |
8 |
|
Dekavil (F8-IL10) |
7 |
|
XT-150 |
6 |
These drugs are in clinical trials for various indications and are being evaluated for safety and efficacy. No drugs in the IL-10 category have been approved by the USFDA for any indication. Drugs are being used that target IL-10 cytokine to treat many diseases and prevent inflammatory responses associated with those diseases causing them. These are used for the treatment of diseases like Rheumatoid Arthritis, Type 2 Diabetes Mellitus, Parkinson’s syndrome, Vascular diseases, Acute Myelogenous Leukemia, Acute Non-Lymphoblastic Leukemia, Follicular lymphoma, Blood disorders and many others. There is an opportunity in the market for the players to launch new products as IL-10 is associated with the pathogenesis of many diseases and hence is a good target.
According to the U.S. Department of Health and Human Services, in 2021, the prevalence rate of Rheumatoid Arthritis (RA) in the USA is about 23.7% making 58.5 million people diagnosed with RA. RA is more common in women than males and adults with fair/poor health compared to adults with very good health. The prevalence of RA is expected to increase in the near future. By 2040, an estimated 78.4 million people above the age of 18 years and above will be diagnosed with RA. Also, According to The Leukaemia and Lymphoma Society, Follicular Lymphoma (FL) is the 2nd most common slow-growing non-Hodgkin’s lymphoma that, accounts for 30% of all lymphomas with an incidence of 15,000 cases/year in the USA. There is an excellent opportunity for the market players to launch new products and enter the market with the rising prevalence of diseases.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Until now, no IL-10 product has been approved by any regulatory agency around the globe.
These are used for the treatment of diseases like Rheumatoid Arthritis, Type 2 Diabetes Mellitus, Parkinson’s syndrome, Vascular diseases, Acute Myelogenous Leukemia, Acute Non-Lymphoblastic Leukemia, Follicular lymphoma, Blood disorders, and many others.
MediciNova, UNION Therapeutics, Eli Lilly, and Pfizer are some of the major market players for IL-10.
Rising incidence of diseases, improvement in technologies, development of new treatment lines in the market, and changing lifestyles leading to various kinds of neurodegenerative and inflammatory disorders are the key opportunities for IL-10 in the market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.